Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bespak and Upperton Partner on Nasal Drug Delivery | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Bespak and Upperton Partner on Nasal Drug Delivery

The CDMO collaboration will combine Bespak’s nasal device portfolio with Upperton’s formulation, analytical and clinical manufacturing expertise.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Editor’s Take: As interest in nasal delivery grows, developers face the challenge of aligning formulation, device and manufacturing suppliers throughout development. This collaboration addresses market need for integrated nasal drug-device product development and commercialization.

Bespak, a specialist contract development and manufacturing organization (CDMO) for inhaled and nasal drug delivery, and Upperton, a CDMO with specialist formulation development expertise, have entered a strategic collaboration to provide an integrated pathway for the development and manufacture of nasal drug-device combination products using Bespak’s expanded proprietary device portfolio.

The collaboration extends Bespak’s nasal capabilities by bringing together its expertise in nasal device design, development engineering, industrialization and commercial supply with Upperton’s formulation development, analytical and clinical manufacturing capabilities. Together, the companies aim to provide a more seamless route from early opportunity assessment and formulation-device development through to clinical supply, scale-up and commercial manufacture.

The new combined offering will support liquid, soft mist and dry powder formulations across Bespak’s newly expanded proprietary single and multi-dose nasal device portfolio. By bringing formulation and device expertise together earlier, the companies aim to reduce development complexity, improve efficiency and accelerate customers’ progress of nasal drug products towards the clinic and into commercial supply.

Chris Hirst, CEO of Bespak, said, “Our collaboration with Upperton adds highly complementary formulation and analytical expertise to our expanded nasal device portfolio, giving customers a more integrated development pathway. By considering the formulation and device as one combination product from an early stage, we can help customers navigate development more efficiently and build a stronger foundation for clinical and commercial success.”

Nikki Whitfield, CEO of Upperton, said, “By combining Upperton’s formulation, analytical and clinical manufacturing expertise with Bespak’s device engineering and commercialization capabilities, we can provide customers with coordinated support across the development journey.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics